2014-03-27 06:01 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Mar 26, 2014--Quintiles today announced that the underwriters of the previously announced secondary public offering of 15 million shares of its common stock have exercised in full their option to purchase an additional 2.25 million shares from certain shareholders of Quintiles. After giving effect to the sale of the additional shares, which was completed on March 26, 2014, the selling shareholders sold a total of 17,250,000 shares of Quintiles' common stock in the offering at a price to the public of $52.00 per share.
Quintiles did not sell any shares in this offering, including the shares subject to the option to purchase additional shares, and did not receive any proceeds from the sale of the shares.
Morgan Stanley, Barclays and J.P. Morgan served as joint book-running managers and as representatives of the underwriters for the offering. Citigroup, Goldman, Sachs & Co., Wells Fargo Securities, BofA Merrill Lynch and Deutsche Bank Securities served as book-running managers for the offering. Baird, William Blair and Jefferies served as lead co-managers, and Guggenheim Securities, Piper Jaffray, Raymond James, RBC Capital Markets and UBS Investment Bank served as co-managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 12, 2014. The offering was made only by means of a prospectus.?Copies of the final prospectus relating to the offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, via telephone: +1 (866) 718-1649 or by email: firstname.lastname@example.org; Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 via telephone: +1 (888) 603-5847, or by email: email@example.com; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or via telephone: +1 (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Quintiles (NYSE: Q) is the world's largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.
Click here to subscribe to Mobile Alerts for Quintiles.
Phil Bridges, Media Relations (firstname.lastname@example.org)
+1-919-998-1653 (office) +1-919-457-6347 (mobile)
Karl Deonanan, Investor Relations (InvestorRelations@quintiles.com)
KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA
INDUSTRY KEYWORD: PRACTICE MANAGEMENT HEALTH BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH GENERAL HEALTH
Copyright Business Wire 2014
PUB: 03/26/2014 04:42 PM/DISC: 03/26/2014 04:42 PM